drugset / Trial / NCT02445976
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
Phase 2
Completed
197 enrolled
Innocrin Pharmaceutical
Prostate Cancer Clinical Trials Consortium · collabProstate Cancer Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and/or abiraterone.
Timeline
- Start
- 2015-05
- Primary completion
- 2018-12
- Completion
- 2019-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seviteronel | Small molecule | — | Oral |